Lung Cancer news and research

Intervals between lung cancer diagnosis and treatment may attribute to health care discrepancies

Research published in the November 2009 issue of the Journal of Thoracic Oncology has found that intervals between lung cancer suspicion, diagnosis and treatment may be attributed to health care system discrepancies.

Congressman Mike Thompson lauded for endorsing the Lung Cancer Mortality Reduction Act

Today, Lung Cancer Alliance (LCA) praised Congressman Mike Thompson (D-CA) for his endorsement of the Lung Cancer Mortality Reduction Act of 2009. Thompson joins Representatives Michael Honda (D-CA), Barbara Lee (D-CA) and Lucille Roybal-Allard (D-CA) in strengthening California's Congressional support for this critically needed legislation.

Computer simulations validate treatment targets for lung cancer

Using computer modeling, the Translational Genomics Research Institute and Scottsdale Healthcare have discovered lung cancer 'pathways' that could become targets for new drugs, according to a scientific paper published online today by the Journal of Thoracic Oncology.

Slavica BioChem scientists reverse multidrug resistance in lung cancer using small molecules

HTDS - The issuer's Serbia based operating subsidiary Slavica BioChem www.slavicabiochem.com brings attention to its Mindup Bioresearch cancer project working on molecular origins of lung cancer: prospects for personalized prevention and therapy. On October 8 2009, the company posted a filing on Pink Sheets titled MindUp Cancer Project.

ImmunoCellular Therapeutics files a patent application concerning its monoclonal antibody product candidate

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today that it has filed a provisional patent application at US Patent Office seeking protection of intellectual property relating to novel glycosylated epitopes present in lung cancer, pancreatic cancer and colon cancer that are targeted by the Company’s ICT-109 monoclonal antibody product candidate.